



Salvage Therapy for Recurrent Prostate Cancer—Optimizing Oncological and Functional Outcomes

Guest Editors:

Dr. Wei Phin Tan

NYU Langone Health, New York,
NY, USA

Dr. Amir H. Lebastchi

Department of Urology,
University of Southern California,
Los Angeles, CA, USA

Deadline for manuscript
submissions:

closed (20 October 2023)

Message from the Guest Editors

Dear Colleagues,

Prostate cancer affects one in eight men in their lifetime. The current standard of care to treat localized prostate cancer is a radical prostatectomy or radiation therapy to the prostate. Following either of these therapies, prostate cancer may recur. Patients with localized recurrence may be a candidate for salvage radiation, salvage prostatectomy or whole gland ablation.

In this special Issue, original research articles and reviews are welcome. Potential topics include but are not limited to the following:

- Work up of PSA recurrence following surgery/radiation.
- Interpretation of mpMRI after focal therapy.
- Role of salvage radical prostatectomy in patients with radiation resistant prostate cancer.
- Role of salvage cryoablation in patients with radiation resistant prostate cancer.
- Role of salvage HIFU in patients with radiation resistant prostate cancer.
- Salvage therapy for patients after focal therapy.
- Management of fistula from salvage therapy to the prostate.
- Incontinence after treatment for prostate cancer.
- Erectile dysfunction after treatment for prostate cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)